AI assistant
Sending…
NovoCure Ltd — Director's Dealing 2022
May 9, 2022
31949_dirs_2022-05-09_ee3953af-83f1-4030-9df0-7a85a645b1d3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-05-05
Reporting Person: GROENHUYSEN WILHELMUS CM (Chief Operating Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-05-05 | Options to Buy Ordinary Shares | $21.9 | G | 1324 | Disposed | 2026-01-12 | Ordinary Shares (1324.0) | Indirect |
| 2022-05-05 | Options to Buy Ordinary Shares | $21.9 | G | 1324 | Acquired | 2026-01-12 | Ordinary Shares (1324.0) | Direct |
Footnotes
F1: Currently exercisable.
F2: By The 2020 Groenhuysen Annuity Trust. Mr. Groenhuysen does not disclaim beneficial ownership.
More from NovoCure Ltd
Proxy Solicitation & Information Statement
2026
May 21
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 24
Regulatory Filings
2026
Apr 9
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 26
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3